JINYU(SH:600201)2016-08-25 16:00Financial Performance - The company's operating revenue for the first half of 2016 was ¥620,221,855.49, representing an increase of 11.18% compared to ¥557,871,337.93 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was ¥283,804,684.23, up 15.42% from ¥245,880,090.60 in the previous year[21]. - The net cash flow from operating activities increased significantly by 311.63%, reaching ¥123,879,776.77 compared to ¥30,094,780.79 in the same period last year[21]. - Basic earnings per share for the first half of 2016 were ¥0.50, an increase of 13.64% from ¥0.44 in the same period last year[22]. - The company's total comprehensive income for the first half of 2016 was ¥486.24 million, compared to ¥386.12 million in the same period last year, showing an increase of approximately 26%[89]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,620,838,627.30, a 2.77% increase from ¥2,550,219,918.58 at the end of the previous year[21]. - The total liabilities decreased to CNY 457,730,524.93 from CNY 481,624,136.55, indicating a reduction of about 5%[79]. - The company's equity attributable to shareholders rose to CNY 2,158,824,025.85 from CNY 2,068,789,589.62[80]. - The ending cash and cash equivalents balance as of June 30, 2016, was ¥901.95 million, down from ¥820.28 million at the end of the previous year[93]. Revenue Sources - Domestic revenue reached CNY 617.84 million, marking a year-on-year increase of 10.89%[39]. - The company received cash from sales of goods and services amounting to ¥477.41 million, up from ¥386.35 million in the same period last year, reflecting a growth of approximately 24%[91]. - The company reported other cash receipts related to operating activities totaling ¥12.10 million, compared to ¥5.02 million in the previous year, indicating a growth of approximately 141%[92]. Research and Development - R&D expenditure rose by 64.05% to CNY 47.54 million, indicating a strong commitment to innovation and product development[30]. - The company successfully launched the Porcine Circovirus Type 2 inactivated vaccine, contributing positively to sales and market competitiveness[33]. - The company is the first in China to produce foot-and-mouth disease vaccines using suspension culture and purification concentration technology, significantly upgrading the domestic veterinary biopharmaceutical industry[40]. Shareholder Information - The total number of shareholders reached 21,340 by the end of the reporting period[66]. - The largest shareholder, Inner Mongolia Agricultural Pharmaceutical Co., Ltd., holds 67,200,000 shares, accounting for 11.73% of total shares[68]. - The company distributed a cash dividend of 4.00 RMB per 10 shares, totaling 22.91 million RMB from the 2015 profit distribution plan[46]. Legal and Regulatory Matters - The company is currently involved in a lawsuit regarding a construction contract, with a claim amounting to approximately 11.11 million RMB, and the case is still under appeal[50]. - The financial report was approved by the board of directors on August 24, 2016, ensuring compliance with regulatory requirements[109]. Accounting Policies - The financial statements are prepared in accordance with the accounting standards, reflecting the company's financial position, operating results, changes in equity, and cash flows accurately[114]. - The company recognizes cash and cash equivalents based on specific criteria, including short-term investments that are easily convertible to known cash[125]. - The company has not made any changes to significant accounting policies or estimates during the reporting period[192][193]. Taxation - The company has a corporate income tax rate of 25% for several subsidiaries, while others benefit from a reduced rate of 15% due to high-tech enterprise status or regional incentives[194][195]. - The subsidiary Jin Yu Bao Ling Biopharmaceutical Co., Ltd. enjoys a preferential income tax rate of 15% effective from January 1, 2011, to December 31, 2020, under the Western Development policy[195].